Adherium Data Reveals Only 8.3% of Asthma Patients Use Inhalers Correctly
Hailie® RPM data reveals only 8.3% of asthma patients use inhalers correctly
Objective data collected from 265 patients through Adherium’s (ASX: ADR) Hailie® Smartinhaler® platform has found that just 8.3% of asthma patients demonstrate optimal inhaler technique. The findings, drawn from the first dataset generated and presented from Adherium’s commercial Remote Patient Monitoring (RPM) program, were presented at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on 30 May 2026. The results validate the platform’s capacity to generate clinical-grade insight at scale while exposing a substantial unmet need in asthma management.
When big ASX news breaks, our subscribers know first
What the data shows — and why it matters
Breaking down the 265-patient cohort
The dataset captures baseline inhaler technique across a broad patient population, with findings that are particularly concerning for users of pressurised metered dose inhalers (pMDIs).
Key cohort characteristics:
- Total patients: 265 (67% female, mean age 41 years, range 2–85 years)
- pMDI preventer inhaler users: 166 patients (62.6% of cohort)
- Ellipta device users: 99 patients (37.4% of cohort)
- Overall optimal technique: only 22 patients (8.3%)
- Optimal technique among pMDI users: 5 patients (3.0%)
- Optimal technique among Ellipta users: 17 patients (17.2%)
- Paediatric patients aged ≤17 years: 76 patients (28.7%); zero demonstrated optimal technique at baseline
The paediatric finding is particularly significant, as pMDIs are commonly the only licensed inhaler option for younger children where dry powder inhalers are not approved for use.
Device-by-device technique breakdown
| Device Type | Patients (n) | Optimal Technique Rate | Sub-Optimal Patients |
|---|---|---|---|
| pMDI | 166 | 3.0% | 161 |
| Ellipta (DPI) | 99 | 17.2% | 82 |
The pMDI finding carries particular weight given that pMDIs account for 47.5% of all inhaler prescriptions in Australia, according to a published analysis of Pharmaceutical Benefits Scheme (PBS) inhaler reimbursements. With only 3.0% of pMDI users demonstrating correct technique in this dataset, the scale of the unmet need across the broader population is considerable.
Understanding RPM and why objective inhaler data changes asthma care
Remote Patient Monitoring, in this context, refers to clinicians remotely accessing real-world medication use data generated by connected devices, enabling oversight of patient behaviour outside the clinic setting.
The Hailie® Smartinhaler® sensor is a jacket-style device that attaches to most inhalers and captures objective measurements of key technique parameters: peak inspiratory flow rate (PIFR), inhalation duration, inhalation volume, shake duration, and device orientation where applicable. PIFR refers to the speed at which a patient draws air into the lungs; inhalation duration measures how long the breath lasts. These are clinically meaningful indicators of whether medication is being delivered effectively to the airways.
Current Global INitiative for Asthma (GINA) guidelines recommend regular inhaler technique checks, but these assessments are typically subjective and conducted in a clinic environment. They may not accurately reflect how a patient uses their inhaler at home on a daily basis. Hailie® data addresses this gap directly by capturing real-world usage at the moment of inhalation.
For investors, the commercial implication is straightforward: a growing RPM patient cohort generates more data, deepens clinical utility, and supports broader integration into healthcare workflows, all of which underpin Adherium’s commercial momentum.
CEO Commentary
“These findings demonstrate the growing power of our Remote Patient Monitoring program, which is now generating objective, high-quality data at scale. are delighted to have our own data presented at a conference for the first time. This first dataset shows how commercially deployed Hailie® SmartInhaler® technology can surface inhaler-technique issues – such as peak inspiratory flow rate and inhalation duration – that may be missed during routine care. By identifying these patterns, clinicians may be able to provide more targeted coaching to improve asthma management and patient outcomes. We are delighted to have Adherium’s own RPM-derived data presented at a conference for the first time. This adds to the growing body of data demonstrating the clinical value of the Hailie® platform.”
— Dawn Bitz, Chief Executive Officer, Adherium
The next major ASX story will hit our subscribers first
From commercial footprint to clinical insight — what’s next for Adherium
Expert validation adds weight to the platform thesis
The EAC presentation drew substantive commentary from a leading allergy and immunology authority, providing external clinical validation of the findings.
Expert Commentary
“Emerging evidence suggests that smart inhaler technology could truly revolutionise the management of diseases like asthma and COPD. The findings suggest that objective sensor technology may help healthcare professionals better identify patients who need support with the fundamental components of inhaler technique, including inspiratory flow and inhalation timing.”
— Dr Allen Meadows, Executive Director of Advocacy and Government Affairs, Past President, American College of Allergy, Asthma & Immunology
Investment significance
The EAC dataset carries several implications for investors assessing the Adherium platform thesis:
- The first conference presentation of RPM-derived data confirms the program is producing publishable, peer-reviewed-calibre insight, not simply device usage logs.
- A growing patient cohort is the engine of this capability: more enrolled patients translate directly into richer data and a stronger clinical evidence base over time.
- The 91.7% sub-optimal technique finding clearly frames the commercial opportunity, with targeted inhaler coaching using Hailie® data representing an evidence-backed use case for both payers and clinicians.
- The pMDI market context (47.5% of Australian inhaler prescriptions) underscores the scale of the addressable problem the platform is positioned to address.
This dataset adds to a growing body of clinical evidence supporting the Hailie® platform, reinforcing the connection between Adherium’s commercial RPM footprint and its capacity to generate meaningful, clinically actionable insight.
Don’t Miss the Next Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at Big News Blast to start receiving real-time coverage today.